No Data
No Data
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair) Dominate the Market
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
Recordati Expects to Close Deal by End of 2024
Recordati: Drug Has Ebitda Margin Above Rare Diseases Average as of 2025
Recordati Expects Minimal Revenue Contribution in 2024
No Data
No Data